J&J(US:JNJ)2026-03-04 02:45Summary of Key Points from the Conference Call Company and Industry Involved - The conference call discusses Johnson & Johnson and its developments in the prostate cancer treatment sector, specifically focusing on the mCRPC (metastatic castration-resistant prostate cancer) treatment landscape. Core Insights and Arguments - Patient Baseline: A total of 51 patients were enrolled, with a median of 3 lines of mCRPC treatment. Among these, 43.1% had previously been treated with docetaxel, and 19.6% had received treatment with Pluvicto [1]. - Efficacy Results: - In the overall population, the PSA50 response rate was 64.7%, and the PSA90 response rate was 35.3%. - For patients who had not been treated with taxanes, the PSA50 response rate was 75.0%, and the PSA90 response rate was 46.4% [1]. - Safety Profile: The incidence of grade ≥3 treatment-related adverse events (TRAE) was reported at 27.5%, with 2.0% specifically related to pasritamig. No cases of any grade of cytokine release syndrome (CRS) were observed, indicating a significant safety advantage [1]. Other Important but Potentially Overlooked Content - Domestic Prostate Cancer TCE Landscape: - Fuhong Hanlin's HLX3902 (CD3/STEAP1/CD28) is currently in the preclinical stage. - Anmai Biotech's EM1031 (CD3/KLK2) has been licensed to Juri Biosciences [1].